SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

• 批准号: 3558190
• 负责人: David A Lipschitz
• 金额: $ 12.69万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-07-15 至 1987-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3558190
• 关键词: combination cancer therapy; computer assisted medical decision making; cooperative study; head /neck neoplasm; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer radiation therapy; patient /disease registry

The primary purpose of this proposal is for the University of Arkansas for Medical Sciences to participate actively in cooperative clinical trials of the Southwest Oncology Group. The Southwest Oncology Group is a major multidisease, therapeutic research organization consisting of 24 full member institutions. The University of Arkansas for Medical Sciences has been a member of the Southwest Oncology Group for 27 years and currently ranks eleventh within the Group in patient accessions. A full complement of 20 physician investigators in a variety of scientific disciplines at the University of Arkansas for Medical Sciences is committed to participation in cancer chemotherapy, surgery, and radiotherapy clinical trials. The University of Arkansas for Medical Sciences has assumed a leadership role in the Group in the study of optimal management of elderly cancer patients. Drs. David A. Lipschitz and Barbara Neilan co-chair the newly-formed Standing Committee on Cancer Management in the Elderly for the Southwest Oncology Group, and are working with the Southwest Oncology Group Statistical Office in a retrospective analysis of Southwest Oncology Group patient records, to address specific questions regarding response and tolerance of elderly cancer patients to chemotherapy. A large number of new cases of head and neck cancer seen at the University of Arkansas for Medical Sciences will be entered onto Southwest Oncology Group protocols or local pilot studies. Likewise, many new cases of melanoma referred to the surgical oncologists will be entered onto cooperative clinical trials. In addition, the University of Arkansas for Medical Sciences has 10 physicians who are active participants in the Southwest Oncology Group Cancer Control Program. Over the past six months, 30 new patients were registered on Cancer Control protocols. Recently, a proposal for a Cancer Center at the University of Arkansas for Medical Sciences was approved by the Board of Trustees. With the establishment of a Cancer Center, the referral of new cancer patients will be increased. Furthermore, the close association of investigators in multidisciplinary oncology clinics at the Cancer Center, will ensure high quality participation of the University of Arkansas for Medical Sciences in multimodal group protocols.

该提议的主要目的是针对阿肯色大学 医学科学将积极参加合作临床试验 西南肿瘤学小组。 西南肿瘤学小组是一个主要 多疾病，治疗研究组织，由24个完整 会员机构。 阿肯色大学医学科学大学 一直是西南肿瘤学集团的成员27年，目前 在患者入门中排名第11位。 各种科学的20位医师调查员的完整补充 阿肯色大学医学科学学科的纪律是 参与癌症化学疗法，手术和放疗临床 试验。 阿肯色大学医学科学大学已经假设 在老年人最佳管理研究中，该小组的领导角色 癌症患者。 博士。 David A. Lipschitz和Barbara Neilan联合主席 老年人新成立的癌症管理常务委员会 西南肿瘤学小组，并正在与西南肿瘤学集团合作 西南肿瘤学小组的回顾性分析中的统计办公室 患者记录，解决有关回应和 老年癌症患者对化学疗法的耐受性。 大量 在阿肯色大学看到的头颈癌的新病例 医学科学将进入西南肿瘤学组协议或 当地的试点研究。 同样，许多新的黑色素瘤病例也提到 手术肿瘤学家将进入合作临床试验。 在 此外，阿肯色大学医学科学大学有10位医生 在西南肿瘤学组癌症控制中的积极参与者 程序。 在过去的六个月中，有30名新患者注册 癌症控制方案。 最近，阿肯色大学癌症中心的提案 医学科学已获得董事会批准。 与 建立癌症中心，新癌症患者的转诊 增加。 此外，调查人员的密切关联 癌症中心的多学科肿瘤学诊所将确保高 阿肯色大学医学科学大学的质量参与 多模式组协议。